Avient Corp Dossier - Source-backed chat

Avient Corp

AVNTNYSE

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)1.18

Intrinsic Value $37.42median of 6 methods · middle span $33-$42based on filings through 30 Jun 2026

Market Price $40.25Price as of 30 Sep 2026

Near fair valueIntrinsic value is 7% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.7B

Enterprise Value $5.1B

Shares Outstanding 92.2M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

Last ex-dividend11 Sep 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Avient Corp is successfully transitioning from commodity PVC roots to a high-margin specialty materials model, focusing on resilient, high-value end markets such as healthcare, defense, and high-performance computing. Despite a mixed macroeconomic backdrop and raw material cost inflation, the company's disciplined execution on pricing, productivity programs, and deleveraging provides a strong foundation for margin expansion and valuation re-rating. Trading at a discount to its historical median and diversified chemical peers, Avient offers an attractive entry point with robust downside support from strong free cash flow generation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$46.00

Mean target$50.86

High · most bullish analyst$56.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$46.0015%

Prolonged demand weakness in consumer and industrial end markets, coupled with severe raw material cost spikes and supply chain disruptions, compresses margins. Pricing power weakens, preventing the company from fully offsetting inflation, while lumpy defense-related timing delays revenue recognition, keeping net leverage above 2.6x and limiting stock performance.

Base CaseCentral scenario

$50.8660%

Matches the consensus mean

Avient delivers on its FY 2026 guidance, supported by steady performance in healthcare and packaging, alongside incremental gains in electronics. Net pricing benefits and cost-saving programs successfully offset mid-single-digit raw material inflation, maintaining stable margins. Free cash flow exceeds $200 million, allowing the company to reduce net leverage below 2.5x by year-end.

Bull CaseUpside scenario

$56.0025%

Accelerated demand recovery in core packaging and electronics segments, combined with sustained double-digit growth in healthcare, drives significant operating leverage. Successful execution of productivity initiatives completely offsets raw material inflation, leading to EBITDA margins exceeding expectations and rapid deleveraging below 2.0x, triggering a valuation multiple expansion toward top-tier specialty chemical peers.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Resilient high-value portfolio with strong secular growth drivers in healthcare, defense, and high-performance computing.
Proven pricing power and robust productivity levers that consistently deliver net price benefits and offset inflationary headwinds.
Strong free cash flow generation (guided at $200M+ for 2026) supporting active debt reduction and balance sheet strengthening.

Key Investment Risks

Sensitivity to cyclical consumer and industrial end markets which represent a significant portion of revenues.
Volatility in hydrocarbon-based raw material costs and potential supply chain disruptions from geopolitical tensions.
Execution risk associated with the recent CFO transition and the timing of lumpy defense-related contracts.

Thesis Invalidation Triggers

Organic sales growth turning persistently negative across multiple consecutive quarters.
Failure to maintain net price benefits, leading to significant gross margin compression.
Free cash flow falling materially below the $200 million target, delaying planned deleveraging.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.